Cardiopulmonary exercise testing and six-minute walk correlations in pulmonary arterial hypertension
- PMID: 16377296
- DOI: 10.1016/j.amjcard.2005.07.129
Cardiopulmonary exercise testing and six-minute walk correlations in pulmonary arterial hypertension
Abstract
In a clinical trial of 178 patients with pulmonary arterial hypertension, treatment improved the 6-minute walk (6MW) distance but not the peak VO2. To clarify this discrepancy, we examined the exercise data from all study sites. Patients received either the endothelin receptor antagonist sitaxsentan or placebo and underwent serial 6MW and cardiopulmonary exercise testing (CPET). In 518 pairs of body weight-adjusted and unadjusted 6MW and CPET data, the correlation between 6MW and peak VO2 was 0.48. In the 4 sites with the highest overall correlation at baseline (r = 0.62 compared with 0.46 for the other 19 sites, p = 0.04), the correlations at baseline (0.66) and at week 12 (0.65) were similar (p = 0.90). However, the correlation increased significantly from baseline (0.34) to week 12 (0.54, p = 0.0005) for the other 19 sites. The correlations between weight-adjusted 6MW distance and peak VO2 for all centers (0.76) were significantly higher than the unadjusted correlations (0.48, p < 0.0001). Improvement in the correlations over time between the 6MW and CPET data at less-experienced sites was most consistent with improved technical skill with increasing experience. Weight adjustment of the 6MW improved its correlation with peak VO2. In conclusion, in future multicenter trials, CPET expertise should be validated at all sites before subject enrollment.
Similar articles
-
Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.J Am Coll Cardiol. 2006 May 16;47(10):2049-56. doi: 10.1016/j.jacc.2006.01.057. Epub 2006 Apr 24. J Am Coll Cardiol. 2006. PMID: 16697324 Clinical Trial.
-
The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect.Vascul Pharmacol. 2005 Jun;43(1):36-9. doi: 10.1016/j.vph.2005.03.003. Vascul Pharmacol. 2005. PMID: 15890561 Clinical Trial.
-
Sitaxsentan therapy for pulmonary arterial hypertension.Am J Respir Crit Care Med. 2004 Feb 15;169(4):441-7. doi: 10.1164/rccm.200307-957OC. Epub 2003 Nov 20. Am J Respir Crit Care Med. 2004. PMID: 14630619 Clinical Trial.
-
Sitaxsentan: a novel endothelin-A receptor antagonist for pulmonary arterial hypertension.Expert Rev Cardiovasc Ther. 2005 Nov;3(6):985-91. doi: 10.1586/14779072.3.6.985. Expert Rev Cardiovasc Ther. 2005. PMID: 16292989 Review.
-
Sitaxsentan for treatment of pulmonary hypertension.Ann Pharmacother. 2007 Jan;41(1):100-5. doi: 10.1345/aph.1G254. Epub 2006 Dec 12. Ann Pharmacother. 2007. PMID: 17164394 Review.
Cited by
-
Wearables, Physical Activity, and Exercise Testing in Liver Disease.Semin Liver Dis. 2021 May;41(2):128-135. doi: 10.1055/s-0040-1716564. Epub 2021 Jan 14. Semin Liver Dis. 2021. PMID: 33788206 Free PMC article.
-
The German adaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR).Health Qual Life Outcomes. 2012 Sep 13;10:110. doi: 10.1186/1477-7525-10-110. Health Qual Life Outcomes. 2012. PMID: 22971041 Free PMC article.
-
Step climbing capacity in patients with pulmonary hypertension.Clin Res Cardiol. 2013 Jan;102(1):51-61. doi: 10.1007/s00392-012-0495-4. Epub 2012 Aug 9. Clin Res Cardiol. 2013. PMID: 22875547
-
Step oximetry test: a validation study.BMJ Open Respir Res. 2018 Aug 3;5(1):e000320. doi: 10.1136/bmjresp-2018-000320. eCollection 2018. BMJ Open Respir Res. 2018. PMID: 30116538 Free PMC article.
-
Fick principle and exercise pulmonary hemodynamic determinants of the six-minute walk distance in pulmonary hypertension.Pulm Circ. 2020 Sep 11;10(3):2045894020957576. doi: 10.1177/2045894020957576. eCollection 2020 Jul-Sep. Pulm Circ. 2020. PMID: 32994925 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical